QSAR models for computer-aided drug design and molecular docking for disorders of the central nervous system and other diseases

Current Topics in Medicinal Chemistry

Volumn 12, Issue 16, 2012, Pages 1731-1733

  Prado Prado, Francisco ^a   García Mera, Xerardo ^b  

^a UNIVERSIDAD DE QUINTANA ROO   (Mexico)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRASE INHIBITOR; MONOAMINE OXIDASE INHIBITOR; PROTEINASE INHIBITOR; RASAGILINE;

ALZHEIMER DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; DEMENTIA; DRUG DESIGN; EDITORIAL; FLOW CYTOMETRY; HUMAN; METABOLOMICS; MOLECULAR DOCKING; MULTIPLE LINEAR REGRESSION ANALYSIS; PARKINSON DISEASE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; QUANTITATIVE STRUCTURE PROPERTY RELATION; COMPUTER AIDED DESIGN;

CENTRAL NERVOUS SYSTEM DISEASES; COMPUTER-AIDED DESIGN; DRUG DESIGN; HUMANS; MOLECULAR DOCKING SIMULATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84875314448     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612803989291     Document Type: Editorial

References (57)

1. González-Díaz, H.; al., e. Topological Indices for Medicinal Chemistry, Biology, Parasitology, Neurological and Social Networks; Hardcover ed.; Transworld Research Network: Kerala, 2010; Vol. 1.
2. Speck-Planche, A.; Kleandrova, V.V.; Luan, F.; Cordeiro, M. N. Chemoinformatics in multi-target drug discovery for anti-cancer therapy: In silico design of potent and versatile anti-brain tumor agents. Anti-cancer Agents Med. Chem., 2011, 12(6), 678-685.
3. Speck-Planche, A.; Kleandrova, V. V. Mol. Divers, 2011.
4. Viña, D.; Uriarte, E.; Orallo, F.; González-Díaz, H. Alignment-free prediction of a drug-target complex network based on parameters of drug connectivity and protein sequence of receptors. Mol. Pharmaceutics, 2009, 6, 825.
5. González-Díaz, H.; Prado-Prado, F.; García-Mera, X.; Alonso, N.; Abeijón, P.; Caamaño, O.; Yañez, M.; Munteanu, C.R.; Pazos, A.; Dea-Ayuela, M.A.; Gómez-Muñoz, M.T.; Garijo, M.M.; Sansano, J.; Ubeira, F.M. J. MIND-BEST: Web server for drugs and target discovery; design, synthesis, and assay of MAO-B inhibitors and theoretical-experimental study of G3PDH protein from Trichomonas gallinae. Proteome Res., 2011, 10, 1698.
6. González-Díaz, H.; Prado-Prado, F.; Sobarzo-Sanchez, E.; Haddad, M.; Maurel Chevalley, S.; Valentin, A.; Quetin-Leclercq, J.; Dea-Ayuela, M. A.; Teresa Gómez-Muñoz, M.; Munteanu, C. R.; Torres-Labandeira, J.; García-Mera, X.; Tapia, R. A.; Ubeira, F. M. NL MIND-BEST: a web server for ligands and proteins discovery--theoretic-experimental study of proteins of Giardia lamblia and new compounds active against Plasmodium falciparum. J. Theor. Biol., 2011, 276, 229.
7. Prado-Prado, F.; García-Mera, X.; Escobar, M.; Sobarzo-Sánchez, E.; Yañez, M.; Riera-Fernández, P.; González-Díaz, H. 2D MI-DRAGON: a new predictor for protein-ligands interactions and theoretic-experimental studies of US FDA drug-target network, oxoisoaporphine inhibitors for MAO-A and human parasite proteins. Eur. J. Med. Chem., 2011, 46, 5838.
8. Santana, L.; Uriarte, E.; González-Díaz, H.; Zagotto, G.; Soto-Otero, R.; Méndez-Álvarez, E. A QSAR model for in silico screening of MAO-A inhibitors. Prediction, synthesis, and biological assay of novel. coumarins. J. Med. Chem., 2006, 49, 1149.
9. Marrero-Ponce, Y. J. Linear indices of the "molecular pseudograph's atom adjacency matrix": definition, significance-interpretation, and application to QSAR analysis of flavone derivatives as HIV-1 integrase inhibitors. Chem. Inf. Comput. Sci., 2004, 44, 2010.
10. Vilar, S.; Santana, L.; Uriarte, E. Probabilistic neural network model for the in silico evaluation of anti-HIV activity and mechanism of action. J. Med. Chem., 2006, 49, 1118.
11. Marrero-Ponce, Y.; Khan, M. T.; Casanola Martin, G. M.; Ather, A.; Sultankhodzhaev, M. N.; Torrens, F.; Rotondo, R. Prediction of tyrosinase inhibition activity using atom-based bilinear indices. ChemMedChem., 2007, 2, 449-478
12. Casanola-Martin, G.M.; Marrero-Ponce, Y.; Khan, M.T.; Ather, A.; Sultan, S.; Torrens, F.; Rotondo, R. TOMOCOMD-CARDD descriptors-based virtual screening of tyrosinase inhibitors: evaluation of different classification model combinations using bond-based linear indices. Bioorg. Med. Chem., 2007, 15, 1483-1503.
13. Casanola-Martin, G.M.; Marrero-Ponce, Y.; Khan, M.T.; Ather, A.; Khan, K.M.; Torrens, F.; Rotondo, R. Dragon method for finding novel tyrosinase inhibitors: Biosilico identification and experimental in vitro assays. Eur. J. Med. Chem., 2007, 42, 1370.
14. Nunez, M.B.; Maguna, F.P.; Okulik, N.B.; Castro, E.A. QSAR modeling of the MAO inhibitory activity of xanthones derivatives. Bioorg. Med. Chem. Lett., 2004, 14, 5611-5617
15. Terada, M.; Inaba, M.; Yano, Y.; Hasuma, T.; Nishizawa, Y.; Morii, H.; Otani, S. Terada, M.; Inaba, M.; Yano, Y.; Hasuma, T.; Nishizawa, Y.; Morii, H.; Otani, S. Growth-inhibitory effect of a high glucose concentration on osteoblast-like cells. Bone, 1998, 22, 17.
16. González-Díaz, H.; González-Díaz, Y.; Santana, L.; Ubeira, F.M.; Uriarte, E. Proteomics, networks and connectivity indices. Proteomics, 2008, 8, 750-778.
17. Zhao, C. J.; Dai, Q. Y. Yao xue xue bao = Acta Pharm. Sin., 2009, 44, 561.
18. Jacob, R.B.; McDougal, O.M. The M-superfamily of conotoxins: a review. Cell. Mol. Life Sci., 2010, 17(1), 17-27.
19. Giuliani, A.; Di Paola, L.; Setola, R. Curr. Proteomics, 2009, 6, 235.
20. Vilar, S.; González-Díaz, H.; Santana, L.; Uriarte, E. A network-QSAR model for prediction of genetic-component biomarkers in human colorectal cancer. J. Theor. Biol., 2009, 261, 449.
21. Concu, R.; Dea-Ayuela, M.A.; Pérez-Montoto, L.G.; Prado-Prado, F.J.; Uriarte, E.; Bolás-Fernández, F.; Podda, G.; Pazos, A.; Munteanu, C.R.; Ubeira, F.M.; González-Díaz, H. 3D entropy and moments prediction of enzyme classes and experimental-theoretic study of peptide fingerprints in Leishmania parasites. Biochim. Biophys. Acta, 2009, 1784-1794.
22. Torrens, F.; Castellano, G. Curr. Proteomics, 2009, 204.
23. Vázquez, J.M.; Aguiar, V.; Seoane, J.A.; Freire, A.; Serantes, J.A.; Dorado, J.; Pazos, A.; Munteanu, C.R. Curr. Proteomics, 2009, 6, 275.
24. González-Díaz, H. Quantitative studies on Structure-Activity and Structure-Property Relationships (QSAR/QSPR). Curr. Top. Med. Chem., 2008, 8, 1554.
25. Ivanciuc, O. Weka machine learning for predicting the phospholipidosis inducing potential. Curr. Top. Med. Chem., 2008, 8, 1691-1709
26. González-Díaz, H.; Prado-Prado, F.; Ubeira, F.M. Predicting antimicrobial drugs and targets with the MARCH-INSIDE approach. Curr. Top. Med. Chem., 2008, 8, 1676-1690.
27. Duardo-Sánchez, A.; Patlewicz, G.; López-Díaz, A. Current topics on software use in medicinal chemistry: intellectual property, taxes, and regulatory issues. Curr. Top. Med. Chem., 2008, 8, 1666-1675.
28. Wang, J.F.; Wei, D.Q.; Chou, K.C. Drug candidates from traditional chinese medicines. Curr. Top. Med. Chem., 2008, 8, 1656-1665.
29. Helguera, A.M.; Combes, R.D.; González, M.P.; Cordeiro, M.N. Applications of 2D descriptors in drug design: a DRAGON tale. Curr. Top. Med. Chem., 2008, 8, 1628-1655.
30. González, M.P.; Terán, C.; Saiz-Urra, L.; Teijeira, M. Variable selection methods in QSAR: an overview. Curr. Top. Med. Chem., 2008, 8, 1606-1627.
31. Caballero, J.; Fernández, M. Artificial neural networks from MATLAB in medicinal chemistry. Bayesian-regularized genetic neural networks (BRGNN): application to the prediction of the antagonistic activity against human platelet thrombin receptor (PAR-1). Curr. Top. Med. Chem., 2008, 8, 1580-1605.
32. Wang, J.F.; Wei, D.Q.; Chou, K.C. Pharmacogenomics and personalized use of drugs. Curr. Top. Med. Chem., 2008, 8, 1573-1579.
33. Vilar, S.; Cozza, G.; Moro, S. Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery. Curr. Top. Med. Chem., 2008, 8, 1555.
34. Prado-Prado, F.J.; García-Mera, X.; González-Díaz, H. Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species. Bioorg. Med. Chem., 2010, 18, 2225.
35. González-Díaz, H. Current Drug Metab., 2010, 11, 283.
36. Khan, M.T. Current Drug Metab., 11, 285.
37. Mrabet, Y.; Semmar, N. Mathematical methods to analysis of topology, functional variability and evolution of metabolic systems based on different decomposition concepts. Curr. Drug Metab., 2010, 11, 315.
38. Martínez-Romero, M.; Vázquez-Naya, J.M.; Rabunal, J.R.; Pita-Fernández, S.; Macenlle, R.; Castro-Alvariño, J.; López-Roses, L.; Ulla, J.L.; Martínez-Calvo, A.V.; Vázquez, S.; Pereira, J.; Porto-Pazos, A.B.; Dorado, J.; Pazos, A.; Munteanu, C.R. Curr. Drug Metab., 2010, 11, 347.
39. Zhong, W.Z.; Zhan, J.; Kang, P.; Yamazaki, S. Gender specific drug metabolism of PF-02341066 in rats--role of sulfoconjugation. Curr. Drug Metab., 2010, 11, 296.
40. Wang, J.F.; Chou, K.C. Curr. Drug Metab., 2010, 11, 342.
41. González-Díaz, H.; Duardo-Sánchez, A.; Ubeira, F.M.; Prado-Prado, F.; Pérez-Montoto, L.G.; Concu, R.; Podda, G.; Shen, B. Review of MARCHINSIDE & complex networks prediction of drugs: ADMET, anti-parasite activity, metabolizing enzymes and cardiotoxicity proteome biomarkers. Curr. Drug Metab., 2010, 11, 379-406.
42. García, I.; Diop, Y.F.; Gomez, G. QSAR & complex network study of the HMGR inhibitors structural diversity. Curr. Drug Metab., 2010, 11, 307-314.
43. Chou, K.C. Curr. Drug Metab., 2010, 11, 369.
44. Concu, R.; Podda, G.; Ubeira, F. M.; González-Díaz, H. Review of QSAR models for enzyme classes of drug targets: Theoretical background and applications in parasites, hosts, and other organisms. Curr. Pharm. Des., 2010, 16, 2710-2723.
45. Estrada, E.; Molina, E.; Nodarse, D.; Uriarte, E. Structural contributions of substrates to their binding to P-Glycoprotein. A TOPS-MODE approach. Curr. Pharm. Des., 2010, 16, 2676.
46. García, I.; Fall, Y.; Gomez, G. QSAR, docking, and CoMFA studies of GSK3 inhibitors. Curr. Pharm. Des., 2010, 16, 2666-2675.
47. González-Díaz, H. Curr. Pharm. Des., 2010, 16, 2598.
48. González-Díaz, H.; Romaris, F.; Duardo-Sánchez, A.; Pérez-Montoto, L.G.; Prado-Prado, F.; Patlewicz, G.; Ubeira, F.M. Curr. Pharm. Des., 2010, 16, 2737.
49. Marrero-Ponce, Y.; Casanola-Martin, G. M.; Khan, M. T.; Torrens, F.; Rescigno, A.; Abad, C. Ligand-based computer-aided discovery of tyrosinase inhibitors. Applications of the TOMOCOMD-CARDD method to the elucidation of new compounds. Curr. Pharm. Des., 2010, 16, 2601.
50. Munteanu, C.R.; Fernández-Blanco, E.; Seoane, J.A.; Izquierdo-Novo, P.; Rodríguez-Fernández, J.A.; Prieto-González, J.M.; Rabunal, J.R.; Pazos, A. Drug discovery and design for complex diseases through QSAR computational methods. Curr. Pharm. Des., 2010, 16, 2640.
51. Roy, K.; Ghosh, G. Exploring QSARs with Extended Topochemical Atom (ETA) indices for modeling chemical and drug toxicity. Curr. Pharm. Des., 2010, 16, 2625.
52. Speck-Planche, A.; Scotti, M. T.; de Paulo-Emerenciano, V. Current pharmaceutical design of antituberculosis drugs: future perspectives. Curr. Pharm. Des., 2010, 16, 2656.
53. Vázquez-Naya, J.M.; Martínez-Romero, M.; Porto-Pazos, A.B.; Novoa, F.; Valladares-Ayerbes, M.; Pereira, J.; Munteanu, C.R.; Dorado, J. Ontologies of drug discovery and design for neurology, cardiology and oncology. Curr. Pharm. Des., 2010, 16, 2724.
54. Chen, J.; Shen, B. Curr. Proteomics, 2009, 6, 228.
55. Chou, K.C. Curr. Proteomics, 2009, 6, 262.
56. González-Díaz, H.; Prado-Prado, F.; Pérez-Montoto, L.G.; Duardo-Sánchez, A.; López-Díaz, A. Curr. Proteomics, 2009, 6, 214.
57. Pérez-Montoto, L.G.; Prado-Prado, F.; Ubeira, F.M.; González-Díaz, H. Curr. Proteomics, 2009, 6, 246.